Fisetin limits Chikungunya virus-induced apoptosis hallmarks in hepatocellular carcinoma cells.
1/5 보강
The study investigated the protective effects of fisetin on chikungunya virus (CHIKV)-induced apoptosis hallmarks in Huh7 cells.
APA
Lani R, Hassandarvish P, AbuBakar S (2025). Fisetin limits Chikungunya virus-induced apoptosis hallmarks in hepatocellular carcinoma cells.. Scientific reports, 15(1), 25140. https://doi.org/10.1038/s41598-025-09213-6
MLA
Lani R, et al.. "Fisetin limits Chikungunya virus-induced apoptosis hallmarks in hepatocellular carcinoma cells.." Scientific reports, vol. 15, no. 1, 2025, pp. 25140.
PMID
40645991 ↗
Abstract 한글 요약
The study investigated the protective effects of fisetin on chikungunya virus (CHIKV)-induced apoptosis hallmarks in Huh7 cells. Fisetin significantly reduced CHIKV RNA levels and viral infectivity, outperforming Z-VAD-FMK and cisplatin. At 30 µM, fisetin markedly decreased (by > 90%) the number of infectious viral particles at 24 and 48 h post-infection (hpi). Fisetin also hindered CHIKV-induced DNA fragmentation, with the lowest levels observed in CHIKV-infected cells treated with fisetin compared to other treatments. Immunoblot analysis revealed that fisetin inhibited caspase-mediated PARP cleavage and significantly reduced cleaved PARP levels, indicating decreased apoptosis. Additionally, fisetin diminished the expression of cleaved caspase-3 and HSP-27 proteins, while restoring HIF-1α protein levels, suggesting a protective role against CHIKV-induced apoptosis. The study highlights the potential of fisetin as an effective antiviral agent against CHIKV through the modulation of apoptosis and oxidative stress pathways. These findings underscore the therapeutic promise of fisetin for treating CHIKV-induced apoptosis and warrant further investigation to explore its clinical applications and optimize its use in antiviral therapy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.